Market Cap 31.34M
Revenue (ttm) 0.00
Net Income (ttm) -110.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 101
Avg Vol 32,663
Day's Range N/A - N/A
Shares Out 108.06M
Stochastic %K 62%
Beta 0.25
Analysts Strong Buy
Price Target $4.80

Company Profile

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcin...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 486 2308
Address:
103 Carnegie Center Drive, Suite 309, Princeton, United States
Latest News on LIANY
No data available.